News | Ablation Systems | May 17, 2018

CardioFocus Announces Successful Live Case Featuring HeartLight X3 System

Next-generation technology for atrial fibrillation showcased at the 21st Annual Prague Workshop on Catheter Ablation

CardioFocus Announces Successful Live Case Featuring HeartLight X3 System

May 17, 2018 — Medical device manufacturer CardioFocus Inc. announced a successful live case featuring its HeartLight X3 System during the annual Prague Workshop on Catheter Ablation, April 21-24 in Prague, Czech Republic.

HeartLight X3 is designed to deliver rapid, continuous, 360-degree lesions for pulmonary vein isolation (PVI) to treat atrial fibrillation. The system does so by building upon the advanced features of the current HeartLight Endoscopic Ablation System — direct tissue visualization, titratable laser energy and compliant balloon technology. The system offers a new "RAPID mode" that leverages a precise motor control system to enable uninterrupted, high-speed lesion creation.

The procedure, broadcast live during the workshop, demonstrated the potential of the HeartLight X3 system. Successful PVI was achieved with a total energy delivery time of under 20 minutes. The case was performed by Petr Neužil, M.D., Ph.D., head of the Department of Cardiology at Na Homolce Hospital in Prague, Czech Republic, and Vivek Y. Reddy, M.D., director of cardiac electrophysiology and Helmsley Trust Professor of Medicine at The Icahn School of Medicine at Mount Sinai. It was part of the ongoing clinical evaluation of the HeartLight X3 System.

"The HeartLight X3 System is demonstrating an unprecedented combination of flexibility and speed," said Neužil "The HeartLight Excalibur Balloon enables wide areas of tissue contact outside of the pulmonary veins, allowing for the system's new RAPID mode to create never-seen-before circumferential, transmural lesion sets. RAPID mode allows for titratable, high-power energy delivery that enables fast ablations. The HeartLight X3 System truly holds the potential to be a breakthrough technology in the AF ablation space."

More than 33 million patients worldwide suffer from AF.1 The most common type of cardiac rhythm disorder, AF prevents blood from being pumped efficiently, which can lead to stroke, weakness, breathlessness, fainting and a significant reduction in quality of life. PVI with the HeartLight X3 System utilizes laser energy to create lines of scar tissue to block abnormal electrical pathways that cause AF.

The clinical evaluation of the HeartLight X3 System is planned to continue throughout 2018, with regulatory submissions to occur thereafter.

The HeartLight X3 System is investigational and not available for sale.

For more information: www.cardiofocus.com

 

References

1 Chugh SS, Havmoeller R, Narayanan K, et al.; Worldwide Epidemiology of Atrial Fibrillation: A Global Burden of Disease 2010 Study. Circulation. 2014 Feb 25;129(8):837-47.

 

Related Content

The SERF VT EFS is a groundbreaking, single-arm observational study designed to evaluate the safety and effectiveness of the Thermedical Durablate catheter to treat VT. #HRS20 #HRS2020 #heartrhythm2020
News | Ablation Systems | May 08, 2020
May 8, 2020 – Results from a first-in-human early feasibility study (EFS) using a saline enhanced radiofrequency (SER
The Affera Inc. pulsed field (PF) energy radiofrequency ablation system. First-in-human trial shows new point-by-point approach provides increased flexibility and efficiency for physicians treating arrhythmia patients. #HRS #HRS2020 #HRS20 #heartrhythm20

The Affera Inc. pulsed field (PF) energy radiofrequency ablation system.

Feature | Ablation Systems | May 08, 2020
May 8, 2020 — A new clinical trial effectively uses pulsed field (PF) energy to treat patients with persistent or par
Noninvasive Radioablation Offers Long-term Benefits to High-risk Heart Arrhythmia Patients
News | Ablation Systems | September 17, 2019
September 17, 2019 — Treating high-risk heart patients with a single, high dose of radiation therapy can dramatically
Biosense Webster Announces Initial Results From First-in-Human QDOT-FAST Study
News | Ablation Systems | May 16, 2019
Johnson & Johnson Medical Devices Companies announced that Biosense Webster, Inc.’s QDot Micro catheter...
CardioFocus Announces Results From HeartLight X3 Ablation System Pivotal Study
News | Ablation Systems | May 16, 2019
CardioFocus Inc. announced the presentation of results from its pivotal confirmatory study evaluating the HeartLight X3...
New Global Consensus Statement Addresses Catheter Ablation of Ventricular Arrhythmias
News | Ablation Systems | May 14, 2019
The Heart Rhythm Society (HRS) in partnership with three other professional societies issued an international consensus...
Netherlands Hospital to Install State-of-the-Art MRI Ablation Center
News | Ablation Systems | May 13, 2019
Imricor announced the signing of a commercial agreement with the Haga Hospital in The Hague, Netherlands to outfit a...
A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beam will ablate for a noninvasive pulmonary vein isolation procedure. Varian acquires, buys, purchases Cyberheart.

A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beams will ablate for a noninvasive pulmonary vein isolation procedure to treat an arrhythmia.

Feature | Ablation Systems | May 10, 2019 | Dave Fornell, Editor
May 10, 2019 — Radiation oncology vendor Varian announced it acquired the start-up company CyberHeart, which has deve